immatics and Roche Sign Cancer Vaccine and Immunotherapy Collaboration

    immatics and Roche Sign Cancer Vaccine and Immunotherapy Collaboration

  PR Newswire

  TUEBINGEN, Germany, and BASEL, Switzerland, November 13, 2013

TUEBINGEN, Germany, and BASEL, Switzerland, November 13, 2013 /PRNewswire/ --

Collaboration spans the discovery, development and commercialisation of cancer
vaccines and other cancer immunotherapies in gastric, lung and prostate cancer

immatics biotechnologies GmbH and Roche (SIX: RO, ROG; OTCQX: RHHBY) today
announced a strategic research and development collaboration covering multiple
cancer vaccines and immunotherapeutics.

The agreement will focus on the research, clinical development and
commercialisation of a number of new tumour-associated peptide (TUMAP)-based
cancer vaccine candidates and other immunotherapies in oncology, targeting
primarily gastric, prostate and non-small cell lung cancer. The most advanced
cancer vaccine candidate covered by the agreement is IMA942, for the treatment
of gastric cancer, which is ready for phase I trials. Roche will be
responsible for the clinical development and commercialisation of all of the
immunotherapies generated by immatics as a result of this collaboration.

In parallel with the clinical development of IMA942 by Roche, immatics will
conduct research on behalf of Roche using its unique XPRESIDENT® technology
platform to identify novel and relevant TUMAP candidates for the development
of cancer vaccines and other compounds targeting cancer peptide antigens,
primarily in gastric, prostate and non-small cell lung cancer. The XPRESIDENT®
discovery platform is to date the only known high-throughput research
technology to directly identify, quantify, and prioritize cancer antigens
recognized by T lymphocytes (type of white blood cell) based on the ability of
the immune system to detect them.

Under the terms of the agreement, immatics will receive an upfront payment of
$17 million and committed research funding plus potential milestone payments
that could reach values in excess of $1 billion and royalties across three
cancer indications, based on sales of the cancer vaccines and immunotherapies
resulting from this agreement.

"Roche is proud to initiate this partnership with immatics , which is widely
recognized as a leader in the field of tumour antigen identification and novel
cancer vaccine development. The wealth of relevant cancer-specific antigens
that we expect to emerge from this research collaboration will provide an
extraordinary opportunity to elicit broad tumour-specific immune responses
upon vaccination, especially when combined with other immunomodulatory
molecules in our pipeline. Discovery of novel antigens also will provide
unique targets for other protein-based anti-cancer agents currently under
development," commented Hy Levitsky, Head of Cancer Immunology Experimental
Medicine at Roche.

Paul Higham, CEO of immatics , said: "We are delighted that Roche through this
alliance has recognized the huge potential of our TUMAP-based approach to
rapidly develop cancer vaccines that we believe hold great promise for cancer
patients in terms of overall survival improvement and quality of life benefits
across a broad range of cancers. It also validates the potential for
XPRESIDENT® identified TUMAPs to play a key role in the development of other
cancer immunotherapies. We are looking forward to working with Roche to make a
significant difference to the outcome for patients with gastric, prostate and
lung cancer."

About  immatics

immatics biotechnologies GmbH is a clinical-stage biopharmaceutical company
developing advanced therapeutic vaccines that are active against cancer.
immatics ' lead product, IMA901, is in a pivotal phase III study after
completing a successful randomised phase II trial in renal cell carcinoma.
immatics ' pipeline also includes IMA910, which has reported encouraging
overall survival data in patients with advanced colorectal cancer (phase I/ II
study completed), and IMA950, which is in phase I studies in patients with
glioma. immatics ' vaccines contain tumour-associated peptides (TUMAPs) to
maximize the chances of clinical success by increasing the number of targets
on cancer cells that they address and are 'drug-like', i.e., fully synthetic,
off-the-shelf, easily scalable, and stable.

immatics ' unique and world-leading technology platform XPRESIDENT® discovers
novel relevant cancer antigens known to be expressed on tumour cells. These
TUMAPs constitute the basis for developing therapeutic cancer vaccines and
other immunotherapies including peptide-targeting compounds such as antibodies
and soluble T-cell receptors. In contrast to widely used existing in silico
and indirect methods to identify peptide antigens, immatics ' TUMAPs are
confirmed to be naturally expressed in primary cancer tissue.

immatics is based in Tuebingen and Martinsried (Munich), Germany, and employs
70 people (FTEs).

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused
healthcare with combined strengths in pharmaceuticals and diagnostics. Roche
is the world's largest biotech company, with truly differentiated medicines in
oncology, infectious diseases, inflammation, metabolism and neuroscience.
Roche is also the world leader in in vitro diagnostics and tissue-based cancer
diagnostics, and a frontrunner in diabetes management. Roche's personalised
healthcare strategy aims at providing medicines and diagnostic tools that
enable tangible improvements in the health, quality of life and survival of
patients. In 2012 Roche had over 82,000 employees worldwide and invested over
8 billion Swiss francs in R&D. The Group posted sales of 45.5 billion Swiss
francs. Genentech, in the United States, is a wholly owned member of the Roche
Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

For additional information on immatics please visit http://www.immatics.com or
contact:

Paul Higham, CEO Dr. Nikola Wiegeler, Assistant to the Management immatics
biotechnologies GmbH Phone: +49-7071-5397-110 E-mail: media@immatics.com
Citigate Dewe RogersonDavid Dible / Chris Gardner / Sita Shah Phone:
+44-207-638-9571 E-mail: david.dible@citigatedr.co.uk For additional
information on Roche please visit http://www.roche.com or contact:Diana Gibson
Roche Partnering Communications E-mail: diana.gibson@roche.com
 
Press spacebar to pause and continue. Press esc to stop.